Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:44 AM
Ignite Modification Date:
2025-12-25 @ 3:44 AM
NCT ID:
NCT01935102
Eligibility Criteria:
Inclusion Criteria:
* diagnosis histologically confirmed of metastatic breast cancer
* age (from 18 to 90 years)
* Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1-2)
* hormonal-receptor status (positive or negative)
* previous adjuvant chemotherapy (none, anthracycline or anthracycline plus taxane)
* previous hormonal therapy (adjuvant or metastatic)disease-free interval from the first diagnosis of breast cancer (≤ or \>12 months)
* extent of disease (≤ or \>3 sites)
* location of disease (viscera or bone)
* disease evaluation (measurable or non-measurable)and bevacizumab maintenance (yes or no).
Exclusion Criteria:
* Patients with human epidermal growth factor receptor type 2 (HER2)-positive
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
90 Years
Study:
NCT01935102
Study Brief:
Protocol Section:
NCT01935102